<DOC>
	<DOCNO>NCT02027779</DOCNO>
	<brief_summary>This study primarily address safety secondarily assess efficacy GreenGene™ F subject severe hemophilia A previously treat ≥50 exposure day GreenGene™ F , without presence inhibitor FVIII ( Factor VIII ) .</brief_summary>
	<brief_title>Safety Efficacy Extension Study GreenGene™ F Previously Treated Patients Diagnosed With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Subjects must participate `` GreenGene™ F_P3 '' , ( Eudra CT number 201200144540 ) pediatric study GreenGene™ F 2 . Have ≥50 previous exposure day GreenGene™ F , document subject 's medical record . 3 . Negative assay FVIII inhibitor inclusion ( &lt; 0.6BU Nijmegen assay ) , i.e . end study `` GreenGene™ F_P3 '' patient enter extension study immediately finish previous phase III study . 4 . Normal liver kidney function 5 . Platelet count ≥ 100,000㎕ 6 . Normal prothrombin time International Normalized Ratio ( INR ) &lt; 1.5 7 . Subjects receive therapy human immunodeficiency virus ( HIV ) hepatitis must stable treatment regimen 8 . Subjects must able withhold FVIII infusion approximately 72 h prior inhibitor assay 9 . Absolute CD4 lymphocyte cell count ≥ 200㎕ 10 . Signed write informed consent form inform consent obtain subject 's legal guardian 11 . Females must lactate pregnant screen Baseline ( document negative betahuman chorionic gonadotropin [ βhCG ] test minimum sensitivity 25 IU/L equivalent unit βhCG ) . A test obtain 72 hour first dose study drug 12 . All female consider childbearing potential unless appropriate age group without know suspected cause ) sterilize surgically ( i.e . bilateral tubal ligation , total hysterectomy bilateral oophorectomy , surgery least one month dose ) 13 . Willing able comply aspect protocol 1 . Presence Screening FVIII inhibitor ≥ 0.6 BU test Nijmegen modification Bethesda assay . 2 . Laboratory clinical evidence portal vein hypertension include , limited , INR &gt; 1.4 , presence splenomegaly and/or spider angioma physical examination and/or history esophageal hemorrhage document esophageal varix 3 . Uncontrolled hypertension ( diastolic blood pressure &gt; 100 mm Hg ) 4 . Hemoglobin &lt; 10 g/dL 5 . Severe renal dysfunction ( creatinine &gt; 2x upper limit normal [ ULN ] , total bilirubin &gt; 2x ULN ) 6 . Liver disease ( alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] &gt; 3x ULN ) 7 . History diabetes metabolic disease 8 . History hypersensitivity serious adverse reaction recombinant plasmaderived FVIII concentrate 9 . History pretreatment prior administration FVIII product ( e.g. , antihistamine ) 10 . Regular use antifibrinolytics medication affect platelet function 11 . Hypersensitivity hamster mouse derive protein 12 . Blood transfusion within 30 day enrollment study 13 . Current participation another investigational drug device study , participate clinical study involve investigational drug device within 30 day enrollment study 14 . Unable unwilling cooperate study procedures 15 . Females pregnant ( positive βhCG test ) breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>GreenGene™ F , Previously Treated Patients</keyword>
</DOC>